ABSTRACT
SPECT-CT integrates CT with SPECT, and can use 18F-fluorodeoxyglucose(FDG) for coincidence imaging. Its imaging can simultaneously indicate the function metabolism information from SPECT and the diagnostic information about anatomy from CT. And the target to no-target(T/NT) ratio can be calculated by using relative semi-quantitative analysis after once imaging. So SPECT-CT is one of the important imaging methods of tumor diagnosis and treatment. However, there is no accepted standard about cut-off level of T/NT ratio in the diagnosis for tumor, also about the selection location of region of interest (ROI) when you calculated the T/NT ratio. If T/NT ratio≥ 2.5 was referred as threshold in the diagnose of malignant tumor, there may be some false positive and false negative. This paper reviews the methods of the selection location of ROI for T/NT ratio in coincidence-CT imaging, and its influence factors, and its value of the diagnosis for benign malignancy, as well as its application progress in tumor diagnosis and treatment. It proves that the increased value by CT to the pure SPECT imaging is that it can more accurately detect lesions anatomically. By the way, it provide more accurate positioning information for the rang of ROI. Thereby, it provide more useful imaging information for clinical biopsy, surgery or the rang of radiotherapy target area.
ABSTRACT
Objective To investigate the influencing factors of 18F-FDG uptaking in head and neck malignancy by SPECT/CT coincidence imaging. Methods 18F-FDG SPECT/CT coincidence imaging was performed in 32 patients with head and neck malignancy after surgery, radiotherapy or radiotherapy + chemotherapy. The radio of target/no target (T/N) was calculated. The gender, age, fasting blood glucose level, size of tumor, location of tumor, pathological classification, de-gree of cell differentiation and treatment modalities were analyzed between groups. Results The single-factor analysis of variance showed that the T/N value was significantly higher in >70 yeas old, group than that of 41-50 yeas old group and 51-60 yeas old group (P5 cm group (P0.05). The multiple linear regression analysis showed that 18F-FDG uptaking in head and neck malignancy (T/N=Y) was related to the age of patients (X2), the diameter of tumor (X4) and the degree of cell differentiation (X9): =-4.389 25+0.053 03 X2+1.617 86 X4+0.718 35 X9. Conclusion Tumor recurrence is more likely to occur in patients with age>70 years old, the diameter of tumor≥2 cm, and the anaplastic head and neck malignancy.We should pay much attention to the diagnosis and follow-up for these pa-tients.
ABSTRACT
Propósito de la revisión: la enfermedad de Parkinson (EP) es un trastorno degenerativo caracterizado clínicamente por presentar temblor en reposo, rigidez y bradicinesia. El propósito es determinar la utilidad de la molécula TRODAT-1 en el diagnóstico de la EP. Metodología: se realizó una búsqueda en las bases de datos: PUBMED, COCHRANE , MEDLINE , LILACS y SCIE LO en un periodo de 10 años desde enero de 1998 a enero de 2008. Se obtuvieron 26 artículos, éstos se analizaron y se seleccionaron 10, de los cuales sólo seis respondían a las necesidades del estudio, de acuerdo con los criterios de inclusión. De los seis artículos analizados, cuatro fueron clasificados como evidencia grado (+) y los dos restantes evidencia grado (-) de acuerdo con las guías NI CE. Todos los artículos revisados reportan una disminución importante en la captación del TRODAT-1 a nivel estriatal, su utilidad en el diagnóstico de EP en estadios tempranos, bajo costo y seguridad. Sólo tres reportan valores de sensibilidad y especificidad, pero su nivel de calidad no permite hacer una comparación de los mismos. Conclusiones: se propone realizar estudios de prueba diagnóstica comparados con el diagnóstico clínico de la enfermedad, que tengan un acuerdo en la forma de plantear las mediciones semicuantitativas de las unidades de captación utilizando las mismas fórmulas para hacerlos comparables (Acta Med Colomb 2010; 35: 119-125).
Purpose: Parkinson disease (PD) is a degenerative disorder. The clinical symptoms of this disease are resting tremor, rigidity and bradykinesia. The purpose of this literature review is to determine the utility of TRODAT -1 in the diagnosis of PD. A search covered PUBMED, COCHRANE, MEDLINE, LILACS and SCIELO databases, between January 1998 and January 2008. Study selection: twenty six articles were obtained with their respective abstracts. After the first review, ten of them were chosen and only six of them met the inclusion criteria. Four articles were classified as grade evidence (+) and two as grade evidence (-) according to NICE guides. All the articles reviewed report significantly decreased striatal uptake of TRODAT-1 in early PD patients, suggesting that this is a useful, safe, and inexpensive tool in the diagnosis of early PD. It was not possible to perform a meta-analysis with the chosen articles because only three of them reported sensitivity and specificity, and each of these used different criteria for their semi-quantitative analyses. This variability makes comparison of the semiquantitative uptake criteria impossible. Conclusions: establishment of a universal technique for quantitation of TRODAT-1 uptake is necessary in order to make meta-analysis viable and allow comparison of the usefulness of this agent among large numbers of patients and multiple populations (Acta Med Colomb 2010; 35: 119-125).